Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial
- PMID: 39741446
- DOI: 10.1176/appi.ajp.20230887
Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial
Abstract
Objective: Evidence suggests that psilocybin-assisted therapy (PAT) leads to durable shifts in personality structure. However, such changes have yet to be characterized in disorders of addiction. In this secondary analysis from a randomized controlled trial, the authors examined the effect of PAT on personality dimensions in patients with alcohol use disorder (AUD), hypothesizing that PAT would attenuate personality abnormalities in AUD and that reductions in trait impulsiveness would be associated with lower drinking.
Methods: Eighty-four adults with AUD were randomized to two medication sessions of either psilocybin (N=44) or active placebo (diphenhydramine; N=40), received 12 weekly psychotherapy sessions, and completed follow-up for an additional 24 weeks. Changes in personality traits (week 36 vs. baseline) were assessed with the revised NEO Personality Inventory; daily alcohol consumption was quantified using the timeline followback.
Results: Relative to the placebo group, the psilocybin group showed significant reductions in neuroticism and increases in extraversion and openness. Secondary analyses showed that reductions in neuroticism were driven by decreases in the facets depression, impulsiveness, and vulnerability; increases in openness were driven by increases in the facets openness toward feelings and fantasy. Across all participants, decreases in impulsiveness were associated with lower posttreatment alcohol consumption, and an exploratory analysis revealed that these associations were strongest among psilocybin-treated participants who continued moderate- or high-risk drinking prior to the first medication session.
Conclusions: PAT elicited durable shifts in personality, suggesting normalization of abnormal personality trait expression in AUD. Further study is needed to clarify whether PAT exerts its beneficial effects by reducing impulsiveness or whether impulsive individuals inherently respond better to PAT.
Keywords: Alcohol Dependence; Impulsiveness; Personality; Psilocybin Therapy; Psychedelic.
Conflict of interest statement
Dr. O’Donnell receives payments from the Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corporation (PBC) as an independent contractor performing training and supervision of research therapists, and she contracts with Lykos Therapeutics to perform education and consultation services. Dr. Ross has received grant support for clinical research from the Council on Spiritual Practices, the Heffter Research Institute, MAPS, the National Cancer Institute, NIDA, Reset Pharmaceuticals, and Usona Institute; he is a director of the NYU Langone Center for Psychedelic Medicine Research and Training Program, which is funded by MindMed; and he is listed as a co-inventor in provisional patent applications related to the use of psilocybin to treat psychiatric and existential distress in cancer (he has waived all rights and has no prospect of financial benefit). Dr. Bogenschutz has received research funding from Bill Linton, B.More, Dr. Bronner’s Family Foundation, the Fournier Family Foundation, the Heffter Research Institute, MAPS-PBC, Mind Medicine, the Riverstyx Foundation, Tilray Canada, and the Turnbull Family Foundation; he serves on advisory boards for Ajna Labs, Bright Minds Biosciences, and Journey Colab; he is a director and principal investigator of the NYU Langone Center for Psychedelic Medicine Research and Training Program, which is funded by MindMed; and he is named as an inventor on patent applications related to the use of psilocybin for alcohol use disorder (he has waived all rights and has no prospect of financial benefit). The other authors report no financial relationships with commercial interests.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
